In agreement with our study, several studies showed that adding SGLT-2 inhibitors to diabetic patients improved hepatic steatosis, serum liver enzymes, body weight, and fasting blood sugar [19, 26–31]. This evidence concerns the gene SLC5A2 and fatty liver disease.